Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Payables (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Payables for 11 consecutive years, with $241471.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables fell 63.44% year-over-year to $241471.0, compared with a TTM value of $241471.0 through Sep 2025, down 63.44%, and an annual FY2024 reading of $415590.0, up 101.49% over the prior year.
  • Payables was $241471.0 for Q3 2025 at Kiora Pharmaceuticals, down from $282537.0 in the prior quarter.
  • Across five years, Payables topped out at $942492.0 in Q1 2025 and bottomed at $125412.0 in Q3 2023.
  • Average Payables over 5 years is $408725.9, with a median of $312662.5 recorded in 2022.
  • The sharpest move saw Payables surged 613.69% in 2021, then plummeted 83.29% in 2023.
  • Year by year, Payables stood at $160621.0 in 2021, then surged by 366.43% to $749192.0 in 2022, then plummeted by 72.47% to $206260.0 in 2023, then soared by 101.49% to $415590.0 in 2024, then plummeted by 41.9% to $241471.0 in 2025.
  • Business Quant data shows Payables for KPRX at $241471.0 in Q3 2025, $282537.0 in Q2 2025, and $942492.0 in Q1 2025.